VectorY

VectorY Therapeutics is an Amsterdam-based biotechnology company founded in August 2020.

The company specializes in vectorized antibody therapies, combining the benefits of antibodies and gene therapy to create long-lasting treatments for neurodegenerative and muscle disorders. VectorY is committed to developing innovative therapies that aim to improve the lives of patients with complex conditions such as ALS, Huntington’s disease, and Parkinson’s disease. The company operates from the Amsterdam Science Park, where it has both research and manufacturing facilities. VectorY has raised approximately $175 million in funding, with key investors including Eli Lilly and Company Foundation and Insight Partners. Its proprietary AAV-based platform allows for the targeted delivery of therapeutic antibodies to specific cells, addressing disease mechanisms that traditional therapies cannot reach. VectorY is currently advancing its pipeline of treatments through pre-clinical trials, with a focus on scalable manufacturing processes to support future clinical and commercial needs.